Tesamorelin vs MOTS-C
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, approved for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy and supported by multicentre randomised trials, later investigator-initiated trials in hepatic fat and cognition, and two 2026 meta-analyses. MOTS-c is a sixteen-amino-acid microprotein encoded within the mitochondrial 12S ribosomal RNA gene, described as a retrograde signal from mitochondria to the nucleus, and its interventional data come almost entirely from rodents and cell culture. They are placed together because both are promoted for fat loss and metabolic effect, and because both appear in the same recent reviews of compounds sold outside regulated medicine. No study has administered both, and their evidence bases are not comparable in kind: one has completed randomised trials with imaging endpoints, the other has never been given to a human being in a controlled study. The papers that engage both are surveys of the peptide market and of anti-doping practice.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered tesamorelin and MOTS-c in the same design, in humans or in animals, and no comparative pharmacology of the two exists. Searches of PubMed and Europe PMC returned four records that engage both compounds, and every one is a review. Two are narrative surveys of approved and unapproved peptides marketed direct to patients, which place tesamorelin among the agents carrying regulatory approval for a defined indication and MOTS-c among those with preclinical data only. A third is a pharmacotherapy review of non-alcoholic fatty liver disease, which set out tesamorelin as a growth hormone-releasing hormone analogue with reported reductions in liver fat and visceral fat and tabulated MOTS-c among earlier-stage drug candidates for the same disease. The fourth is the annual banned-substance review from an anti-doping laboratory, which records tesamorelin's class among prohibited growth hormone-releasing agents and notes the addition of MOTS-c to the prohibited list as an example under the section covering agents that modify metabolic function. None of those reviews reports an experiment in which the two were compared, and none makes a claim about relative potency, efficacy or safety.
The 4 publications that cover both
- 01Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Medicine · narrative review of approved and unapproved peptides marketed direct to patients, covering AOD-9604, BPC-157, CJC-1295, follistatin-344, GHK-Cu, ipamorelin, MOTS-c, sermorelin, elamipretide, tesamorelin, thymosin beta-4 and TB-500
The review reported that many unapproved peptides demonstrated favourable tissue repair and metabolic outcomes in animal models while rigorous human safety data were scarce and the potential for serious harm to patients existed. It separated peptides that had passed a rigorous approval process, among them tesamorelin, from a parallel grey market of unapproved compounds including MOTS-c, and discussed the placebo effect, amplified by social media, as a mediator of perceived efficacy.
- 02Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · International Journal of Molecular Sciences · review of 106 articles prioritising systematic reviews, meta-analyses and randomised controlled trials, covering peptides used in metabolic, endocrine and aesthetic settings
The review described tesamorelin as a high-potency growth hormone-releasing hormone analogue approved for HIV-associated lipodystrophy because it reduces visceral fat, and stated that outside that context its benefit was limited. It grouped MOTS-c with elamipretide as mitochondrial peptides acting on mitochondrial dysfunction, and recorded that MOTS-c currently had no approved therapeutic application, with extensive preclinical data supporting future clinical trials in metabolic disease, cardiovascular complications, ischaemia-reperfusion injury and chronic pain.
- 03Review2022
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Prikhodko VA, et al. · Biomedicines · review of emerging molecular targets and drug candidates for non-alcoholic fatty liver disease, with candidates tabulated by mechanism and development phase
The review described tesamorelin as a growth hormone-releasing hormone analogue thought to stimulate lipolysis by raising endogenous growth hormone while maintaining feedback inhibition and limiting toxicity compared with native growth hormone, and reported that it reduced liver fat content and visceral fat in a preliminary study in antiretroviral-treated patients with HIV-associated lipodystrophy. MOTS-c appeared in the same review's tabulation of drug candidates under investigation for the disease, at an earlier development stage.
- 04Review2026
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025
Thevis M, et al. · Drug Testing and Analysis · annual review of analytical approaches in human sports drug testing, structured around the classes of the World Anti-Doping Agency prohibited list
The review recorded that modifications to the prohibited list from the previous edition included the addition of the peptide referred to as mitochondrial open reading frame of the 12S rRNA-c, MOTS-c, as an example under section S4.4.1. Tesamorelin appears in the same review within the tabulated prohibited classes covering growth hormone-releasing agents. The paper is an analytical and regulatory survey and reports no efficacy data for either compound.
Side by side.
| Tesamorelin | MOTS-C | |
|---|---|---|
| Evidence maturity | Approved drug | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 11 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 44-amino-acid synthetic analogue of human growth hormone-releasing factor, carrying a trans-3-hexenoyl modification on the N-terminal tyrosine that non-clinical work reported slowed enzymatic degradation and prolonged plasma kinetics. | A 16-amino-acid microprotein encoded within the mitochondrial 12S ribosomal RNA gene, so it originates from the mitochondrial rather than the nuclear genome and is described as an endogenous retrograde signalling molecule. |
| Mechanism as described in the literature | Acts at the growth hormone-releasing hormone receptor on pituitary somatotrophs, raising endogenous pulsatile growth hormone and IGF-1 while leaving feedback regulation intact. | Reported to activate AMPK, to target the folate-methionine one-carbon cycle, to bind and activate casein kinase 2 in skeletal muscle, and to translocate to the nucleus to alter stress-response gene expression. Effects in mouse models depended on intact PGC-1alpha and AMPK signalling. |
| Size of the evidence base | Multicentre randomised placebo-controlled trials in HIV-associated lipodystrophy with extension phases, investigator-initiated randomised trials in hepatic fat and cognition, and two 2026 meta-analyses pooling four and five randomised controlled trials respectively. | No controlled trial of administration in humans exists. The interventional literature is rodent and cell culture, and the human literature is observational biomarker work plus one mitochondrial genotype association analysed across cohorts totalling more than 27,000 participants. |
| Best-characterised finding | Reduction in visceral adipose tissue in people with HIV and abdominal fat accumulation, with the pivotal trial reporting a 15.2% decrease against a 5.0% increase on placebo, and reductions in hepatic fat fraction in later randomised trials. | In mice, administration prevented age-dependent and diet-induced insulin resistance and diet-induced obesity, and improved physical performance across young, middle-aged and old animals. In humans, acute exercise was associated with increased endogenous expression in skeletal muscle and plasma. |
| Human data | Randomised controlled trials with imaging endpoints, safety extension data and pooled meta-analyses, alongside neurocognitive trials that have been small and inconsistent. | Entirely observational or genetic. Circulating concentrations have been measured across metabolic, cardiovascular, renal and reproductive conditions, and move in opposite directions between them, being lower in diabetes and higher in obesity and acute coronary syndrome. |
| Safety signals reported | Arthralgia, myalgia, paraesthesia and injection-site reactions were recorded in the pooled trial analyses, along with IGF-1 elevation, and one meta-analysis reported higher discontinuation rates in treatment arms. | No human safety data from administration exist, because no controlled human administration study has been conducted. The reviews that name the compound record the absence of such data rather than a favourable profile. |
| Regulatory and anti-doping status | Approved for one indication, HIV-associated lipodystrophy. Growth hormone-releasing factor analogues are prohibited in sport and are the subject of a dedicated detection literature in urine and blood. | Unapproved in every jurisdiction. The 2026 banned-substance review records MOTS-c having been added to the prohibited list as an example under section S4.4.1, so it is a prohibited substance without ever having been an approved medicine. |
| Basis of most marketing claims | Extension of a visceral-fat result obtained in one clinical population to general body composition, ageing and cognition, where the controlled evidence is small, mixed or absent. | Extension of rodent administration studies and human observational associations to claims of fat loss, endurance and healthspan in people, which no controlled human study has tested. |
And what it does not.
The two compounds have never been studied together, and the gap between their evidence bases is the substantive finding. Tesamorelin has completed randomised placebo-controlled trials with objective imaging endpoints, an approval for one indication, meta-analyses pooling those trials and a documented adverse-effect profile; what it lacks is controlled evidence outside HIV-associated visceral adiposity and hepatic steatosis. MOTS-c has not been administered to humans in a controlled study at all, so it has no efficacy result, no dose-response, no pharmacokinetics and no safety record in people. Its rodent data are genuinely interesting and mechanistically detailed, and its human data are real but observational, with circulating concentrations moving in opposite directions across conditions in a way the reviews describe as unsettled. The four publications that name both compounds are surveys of the peptide market and of anti-doping regulation, and each of them sorts the two into different categories rather than comparing them. Nothing published supports treating them as alternatives for the same purpose.
Common questions.
- Has MOTS-c ever been given to humans in a controlled study?
No controlled clinical trial has administered exogenous MOTS-c to humans, so its efficacy, dosing, pharmacokinetics and safety in people are unestablished. The human literature consists of observational measurements of circulating concentrations across metabolic, cardiovascular, renal and reproductive conditions, plus one mitochondrial polymorphism in the coding region associated with type 2 diabetes risk in East Asian men. Every interventional result reported for the peptide comes from rodent models or cell culture.
- Do the two compounds act on the same pathway?
They do not overlap. Tesamorelin acts at the growth hormone-releasing hormone receptor on pituitary somatotrophs, raising endogenous pulsatile growth hormone and IGF-1 through a classical endocrine pathway. MOTS-c is described as a mitochondrial-derived signalling peptide reported to activate AMPK, to engage the folate-methionine one-carbon cycle, to bind casein kinase 2 in skeletal muscle and to enter the nucleus to alter stress-response gene expression. No published work connects the two mechanisms.
- Why do circulating MOTS-c measurements point in different directions?
Because the biomarker behaves differently across conditions and the assays differ between studies. A systematic review and meta-analysis of seven studies reported lower concentrations in diabetes but higher concentrations in obesity, and case-control work found higher levels in acute coronary syndrome than in controls. Other studies reported lower levels in polycystic ovary syndrome and unchanged levels after surgical weight loss. The authors of these papers note small study numbers and inconsistent assay methods, so interpretation as a marker is not settled.
- Is either compound permitted in competitive sport?
Neither is. Growth hormone-releasing factor analogues including tesamorelin fall under the prohibited categories covering growth hormone-releasing agents, and a dedicated analytical literature exists for detecting them in urine and blood. The 2026 annual banned-substance review records that MOTS-c was added to the prohibited list as an example under section S4.4.1. MOTS-c therefore became a prohibited substance without ever having been approved as a medicine in any jurisdiction.
- What has tesamorelin shown outside HIV-associated fat accumulation?
Less than inside it. Randomised work extended the compound to hepatic fat in fatty liver disease in people with HIV, where hepatic fat fraction fell relative to placebo. Cognitive results have been inconsistent: an earlier controlled trial reported a favourable effect on a composite cognitive measure, a 2026 randomised study in 22 adults found no significant change, and a phase 2 trial in people with HIV and abdominal obesity found no significant between-group difference. A trial of the compound alongside exercise has published a protocol without results.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.